Zota Health Care acquires 2 million shares of KMHP Ventures for Rs 2 crore

What Zota Health Care announced

Zota Health Care Limited (NSE: ZOTA) informed the stock exchange that it has acquired 2,000,000 equity shares of KMHP Ventures Limited by way of subscription to a right issue. The subscription price was Rs 10 per share, amounting to a total cash outlay of Rs 2 crore. The acquisition was completed on 22 June 2026, the same day the filing was made with the National Stock Exchange.

The shares purchased represent a further capital infusion into KMHP Ventures, which is already a wholly‑owned subsidiary of Zota Health Care. The transaction does not alter the subsidiary status; KMHP continues to be 100 % owned by Zota.

Details of the acquisition

• Target entity: KMHP Ventures Limited, incorporated on 13 January 2026, engaged in the pharmaceutical sector.
• Business focus: Development of a retail chain under the brand ‘Ugo Generic’, operating both Business‑to‑Business (B2B) and Business‑to‑Consumer (B2C) models. The plan envisions owned stores and the onboarding of roughly 12.5 million retail pharmacies across India.
• Financial snapshot: For FY 2025‑26, KMHP reported nil turnover and a paid‑up share capital of Rs 10 lakh. No turnover figures are available for FY 2024‑25 and FY 2023‑24.
• Consideration: Pure cash payment of Rs 2 crore, derived from the right‑issue subscription price of Rs 10 per share.
• Related‑party status: The filing confirms that the transaction does not fall within the ambit of related‑party transactions; promoters or promoter groups have no interest in KMHP.
• Regulatory approvals: No governmental or regulatory approvals were required for the acquisition.
• Completion timeline: The acquisition was effected on the same day as the filing – 22 June 2026.

Key facts at a glance

Why this matters for investors

The transaction is a strategic capital infusion into a subsidiary that is poised to enter the fast‑growing generic medicines retail market. By funding KMHP’s rollout of the Ugo Generic brand, Zota Health Care is positioning itself to capture a share of the estimated ₹1 lakh crore Indian generic drug market. The cash outlay of Rs 2 crore is modest relative to Zota’s overall market capitalisation, implying limited dilution or financial strain.

Because the acquisition does not involve related parties, it satisfies SEBI’s disclosure norms and reassures investors that the deal was executed at arm’s length. The absence of required regulatory clearances also suggests a smoother implementation timeline for KMHP’s expansion plans.

Investors should note that KMHP reported nil turnover for the most recent financial year, indicating that the subsidiary is still in a pre‑revenue phase. Consequently, the immediate financial impact on Zota’s consolidated results is expected to be limited, with the primary benefit being future growth potential rather than current earnings contribution.

Conclusion

Zota Health Care Limited has completed a cash‑based right‑issue subscription for 2 million shares of its subsidiary KMHP Ventures, spending Rs 2 crore. The move funds KMHP’s ambitious plan to launch the Ugo Generic retail chain across India. While the subsidiary currently reports no revenue, the investment aligns with Zota’s strategic intent to expand its footprint in the pharmaceutical retail space. No further approvals are pending, and the subsidiary remains wholly owned, leaving the broader corporate structure unchanged.

“The acquisition is a strategic investment to support KMHP’s rollout of a pan‑India generic medicines retail network.” – Zota Health Care Limited, filing dated 22 June 2026